Bioscience, Inc. has strengthened its management team with the appointment of Rhea Williams, MPH, as Head of Regulatory Affairs & Quality Assurance and Varun Khurana, PhD, as Senior Director of Research & Development. Rhea Williams, MPH, brings over 25 years of experience in drug development, regulatory affairs and quality assurance. She has supported the development of small and large molecules and worked with teams focused on serious and life-threatening diseases and potential treatments in the areas of neurology, hematology, oncology, women’s health, cardiology, and ophthalmology. Dr. Varun Khurana brings over seven years of comprehensive experience in pre-formulation and formulation development, technical transfer, CMC, CMO/CRO management and regulatory submissions for innovative and complex drug development programs. His expertise encompasses product ideation, portfolio strategy, due diligence, lifecycle management and intellectual property strategy. Dr. Khurana has worked on several dosage forms including ophthalmic, injectable, oral, and sublingual. Ms. Williams held management positions at Johnson & Johnson, Schering-Plough, and Eisai, and supported large and small pharmaceutical companies as a consultant. Additionally, she served as CEO and principal consultant of Secord Inc. Dr. Khurana served as Principal Scientist at GlaxoSmithKline, where he was responsible for creating, leading, and driving innovation to strengthen GSK’s product portfolio.
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.